[1] |
Newell LF, Cook RJ. Advances in acute myeloid leukemia[J]. BMJ, 2021, 375:n2026.
|
[2] |
Calvo KR, Hickstein DD. The spectrum of GATA2 deficiency syndrome[J]. Blood, 2023, 141(13): 1524-1532.
|
[3] |
Belohlavkova P, Hrochova K, Fatorova I, et al. MonoMAC syndrome with GATA2 novel mutation[J]. Leuk Res Rep, 2022, 18:100346.
|
[4] |
Mulet-Lazaro R, van Herk S, Erpelinck C, et al. Allele-specific expression of GATA2 due to epigenetic dysregulation in CEBPA double-mutant AML[J]. Blood, 2021, 138(2): 160-177.
doi: 10.1182/blood.2020009244
pmid: 33831168
|
[5] |
Bullinger L. CEBPA mutations in AML[J]. Blood, 139(1): 6-7.
|
[6] |
Russo V. Cholesterol: a putative oncogenic driver for DLBCL[J]. Blood, 2022, 139(1): 5-6.
doi: 10.1182/blood.2021014300
pmid: 34989774
|
[7] |
West RR, Bauer TR, Tuschong LM, et al. A novel GATA2 distal enhancer mutation results in MonoMAC syndrome in 2 second cousins[J]. Blood Adv, 2023, 7(20): 6351-6363.
|
[8] |
Wakita S, Sakaguchi M, Oh I, et al. Prognostic impact of CEBPA bZIP domain mutation in acute myeloid leukemia[J]. Blood Adv, 2022, 6(1):238-247.
|
[9] |
Taube F, Georgi JA, Kramer M, et al. CEBPA mutations in 4708 patients with acute myeloid leukemia: differential impact of bZIP and TAD mutations on outcome[J]. Blood, 2022, 139(1): 87-103.
|
[10] |
Ren H, Hong M, Feng J, et al. GATA2 mutant variant allele frequency may reflect prognosis in Chinese adult patients with de novo cytogenetically normal acute myeloid leukemia[J]. Biomol Biomed. 2024. Epub ahead of print.
|
[11] |
黄佳瑜, 刘为星, 连芸, 等. 标准剂量IA方案诱导治疗242例初诊急性髓系白血病的临床观察[J]. 中华血液学杂志, 2018, 39(4):331-335.
|
[12] |
张露雅. 去甲氧柔红霉素、柔红霉素分别联合阿糖胞苷诱导治疗初治成人急性髓系白血病的疗效及预后分析[J]. 罕少疾病杂志, 2022, 29(7):107-109.
|
[13] |
韦梦红, 夏海龙. venetodax 联合阿扎胞苷治疗初诊不适合强化疗的急性髓系白血病患者的疗效观察[J]. 中国现代医生, 2024, 62(1):74-77.
|
[14] |
Morsia E, McCullough K, Joshi M, et al. Venetoclax and hypomethylating agents in acute myeloid leukemia[J]. Am J Hematol, 2020, 95(12): 1511-1521.
|
[15] |
Mishra R, Zokaei Nikoo M, Veeraballi S, et al. Venetoclax and hypomethylating agent combination in myeloid malignancies[J]. Int J Mol Sci, 2023, 25(1):484.
|